Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Ghatage

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Gynecologic Oncology|January 30, 2017
Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapyC K Ho, E N Kornaga, A C Klimowicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studyB J Monk, P Ghatage, T Parekh, et al.
Gynecologic Oncology|August 14, 2018
Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomesS P Bisch, T Wells, L Gramlich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.
Current Oncology (Toronto, Ont.)|October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspectiveA M Oza, V Castonguay, D Tsoref, et al.
British Journal of Cancer|October 29, 2014
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium studyM Köbel, J Madore, S J Ramus, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 28, 2022
2021 Canadian Surgery Forum: Virtual, online Sept. 21-24, 2021G Johnson, A Vergis, B Unger, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Gynecologic Oncology|January 30, 2017
Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapyC K Ho, E N Kornaga, A C Klimowicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studyB J Monk, P Ghatage, T Parekh, et al.
Gynecologic Oncology|August 14, 2018
Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomesS P Bisch, T Wells, L Gramlich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.
Current Oncology (Toronto, Ont.)|October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspectiveA M Oza, V Castonguay, D Tsoref, et al.
British Journal of Cancer|October 29, 2014
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium studyM Köbel, J Madore, S J Ramus, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 28, 2022
2021 Canadian Surgery Forum: Virtual, online Sept. 21-24, 2021G Johnson, A Vergis, B Unger, et al.
Pageof 2